Today, Evotec have announced a new multi-year master research collaboration and option and license agreement with Pfizer. The research, which will initially focus on early discovery research for metabolic and infectious diseases, will be carried out at Evotec's sites in France, including Campus Curie in Toulouse. Find out more about this new collaboration: https://lnkd.in/dzdA3AxX #news #pharmaceuticals #drugdiscovery #pfizer #evotec
PharmiWeb.jobs: Global Life Science Jobs’ Post
More Relevant Posts
-
$100 million partnership leads to 10 potential drugs? ➡️ Last week, Flagship Pioneering and Pfizer have agreed to each invest $50 million to to develop novel technologies towards bigger disease areas. Under the terms of the agreement, Flagship-backed companies could receive up to $700 million in milestones and royalties upon the successful launch and sale of any of the experimental treatments discovered and developed under partnership. "This collaboration is an exciting opportunity for Pfizer to bring deep scientific expertise and apply our development and regulatory strength to Flagship's diverse portfolio of technology platforms," said Pfizer's CSO Mikael Dolsten. Exciting news.. read more via the link below ⬇️ #drugdiscovery #biotechnology #pharmaceuticals #immunology
Pfizer, Flagship Pioneering to invest $100 mln in drug discovery
reuters.com
-
Chronic Hepatitis B Virus Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ligand Pharma, Dicerna, Vir Biotechnology, Roche: Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 50 key pharma and biotech companies are working on 55 pipeline drugs in the Chronic Hepatitis B Virus therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
Chronic Hepatitis B Virus Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ligand Pharma, Dicerna, Vir Biotechnology, Roche
https://www.abnewswire.com/pressreleases
-
Registration is now open for our next round of meetings happening in #sanfrancisco in September 2023. For more information, agendas and to register, please follow links below. US West Coast - San Francisco: Antibody Therapeutics Xchange, September 25th, 2023 https://lnkd.in/eMEWjqy8 Immuno-Oncology Xchange, September 26th, 2023 https://lnkd.in/eaGSSrU7 CNS Therapeutics Xchange, September 27th, 2023 https://lnkd.in/eMUXztje Augmented Intelligence in Drug Discovery Xchange, September 28th, 2023 https://lnkd.in/ejiiDzFJ Please note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #therapeutics #therapies #immunotherapy #immunooncology #antibodytherapeutics #antibodyoptimisation #antibodydiscovery #ai #augmentedintelligence #cns
-
-
Registration is now open for our next round of meetings happening in #sanfrancisco in September 2023. For more information, agendas and to register, please follow links below. US West Coast - San Francisco: Antibody Therapeutics Xchange, September 25th, 2023 https://lnkd.in/eMEWjqy8 Immuno-Oncology Xchange, September 26th, 2023 https://lnkd.in/eaGSSrU7 CNS Therapeutics Xchange, September 27th, 2023 https://lnkd.in/eMUXztje Augmented Intelligence in Drug Discovery Xchange, September 28th, 2023 https://lnkd.in/ejiiDzFJ Please note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #therapeutics #therapies #immunotherapy #immunooncology #antibodytherapeutics #antibodyoptimisation #antibodydiscovery #ai #augmentedintelligence #cns
-
-
#ACROHighlights [Featured Product] 🚀 Another Biotech Secures Blockbuster $1.71 Billion Deal with Autoimmune Leader On June 13, 2024, global pharmaceutical giant AbbVie secured a $1.71 billion cooperation agreement with Beijing Mingjie Biopharma (FutureGen). This partnership grants AbbVie exclusive worldwide rights to develop, produce, and commercialize Mingjie Biopharma's preclinical TL1A antibody drug pipeline, FG-M701. 🌐💊 In 2023, the autoimmune disease field witnessed four significant transactions, three of which involved the TL1A target. This trend underscores TL1A's enormous potential in the market, poised to become a game-changer in autoimmune and inflammatory bowel disease treatments. 🔬🌟 To support the development of targeted TL1A/DR3 antibody drugs, we offer a comprehensive range of products: - TL1A recombinant proteins (natural trimer validated by cell assay) - DR3 recombinant proteins - TL1A cell lines - TL1A inhibitor screening assay kit (coming soon) We're here to meet all your TL1A drug development needs! 🧬🔧 Learn more: https://smpl.is/9d89g #Biotech #Pharma #AutoimmuneDisease #Innovation #DrugDevelopment #Healthcare
-
-
Registration is now open for our next round of meetings happening in #sanfrancisco in September 2023. For more information, agendas and to register, please follow links below. US West Coast - San Francisco: Antibody Therapeutics Xchange, September 25th, 2023 https://lnkd.in/eMEWjqy8 Immuno-Oncology Xchange, September 26th, 2023 https://lnkd.in/eaGSSrU7 CNS Therapeutics Xchange, September 27th, 2023 https://lnkd.in/eMUXztje Augmented Intelligence in Drug Discovery Xchange, September 28th, 2023 https://lnkd.in/ejiiDzFJ Please note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #therapeutics #therapies #immunotherapy #immunooncology #antibodytherapeutics #antibodyoptimisation #antibodydiscovery #ai #augmentedintelligence #cns
-
-
Chronic Hepatitis B Virus Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ligand Pharma, Dicerna, Vir Biotechnology, Roche: Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 50 key pharma and biotech companies are working on 55 pipeline drugs in the Chronic Hepatitis B Virus therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
Chronic Hepatitis B Virus Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ligand Pharma, Dicerna, Vir Biotechnology, Roche
https://www.abnewswire.com/pressreleases
-
If you missed us in Zurich....We're in #SanDiego for the first round of our #2024 roundtable xchanges. Join us then! For more information, agendas and to book your spot, please follow links below. US - San Diego: Antibody Therapeutics Xchange, February 26th, 2024 https://lnkd.in/ew2y26Yv Immuno-Oncology Xchange, February 27th, 2024 https://lnkd.in/eRab_BEE Oligonucleotide Therapeutics Xchange, February 28th, 2024 https://lnkd.in/eXpNsFQd Advanced Therapies Xchange, February 29th, 2024 https://lnkd.in/eQAUQU7Y Please note: Registration is only open to Senior Scientists and above actively working in the #pharmaceuticals / #biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #therapeutics #therapies #immunotherapy #immunooncology #antibodytherapeutics #antibodyoptimisation #antibodydiscovery #ai #augmentedintelligence #cns
-
-
𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝘀𝗲𝗰𝗼𝗻𝗱 𝗵𝗶𝗴𝗵𝗲𝘀𝘁 𝗻𝘂𝗺𝗯𝗲𝗿 𝗼𝗳 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝟯𝟬 𝘆𝗲𝗮𝗿𝘀! The FDA greenlit 55 new drugs in 2023, an impressive surge of nearly 50% compared to the previous year. This included a substantial uptick in both small molecules and biologics, and featured several groundbreaking first-in-class or disease-specific approvals. The drug approval landscape witnessed notable strides being made across major therapeutic areas, orphan diseases, and emerging modalities. This overview reflects on the noteworthy developments and key highlights of 2023. In addition, we will explore potential trends and pivotal events to anticipate in the dynamic landscape of drug approvals as we look ahead at 2024. Learn more in this summary: https://okt.to/RZU2jw #FDAApproval #pharma #drugsafety #ScienceForASaferWorld
Novel Therapies Approvals by FDA | LGC Standards
lgcstandards.com
-
If you missed us in Zurich....We're in #SanDiego for the first round of our #2024 roundtable xchanges. Join us then! For more information, agendas and to book your spot, please follow links below. US - San Diego: Antibody Therapeutics Xchange, February 26th, 2024 https://lnkd.in/ew2y26Yv Immuno-Oncology Xchange, February 27th, 2024 https://lnkd.in/eRab_BEE Oligonucleotide Therapeutics Xchange, February 28th, 2024 https://lnkd.in/eXpNsFQd Advanced Therapies Xchange, February 29th, 2024 https://lnkd.in/eQAUQU7Y Please note: Registration is only open to Senior Scientists and above actively working in the #pharmaceuticals / #biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #therapeutics #therapies #immunotherapy #immunooncology #antibodytherapeutics #antibodyoptimisation #antibodydiscovery #ai #augmentedintelligence #cns
-
